The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the ...

Request To Download Free Sample of This Strategic Report@ COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

But enrollment for all clinical studies of infant RSV vaccines is now on hold due to safety concerns, explained a Dec. 11 ...

GSK is hosting the third annual RespiVerse Meeting in Bangkok, Thailand. The event brings together renowned international ...

The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

The revenue for GSK-3810109 is expected to reach an annual total of $132 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Researchers identified optimal assessment tools for RSV, influenza, and hMPV that accurately supplement the identification of ...

Data since the early 1900s indicate that influenza might increase the risk for cardiovascular complications. Today, we know ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...